Daré Bioscience to present sildenafil cream study data at SMSNA
Daré Bioscience (NASDAQ:DARE) will present Phase 1 study data on its Sildenafil Cream at a medical conference. The study showed lower plasma concentration and systemic exposure compared to oral sildenafil, with no serious adverse events. The cream is being developed for female sexual arousal disorder, with ongoing clinical trials.
How this was made
The 30-second read
Why it matters
The Phase 1 data provide the first safety and exposure metrics, potentially de‑risking the program.
Market read
First disclosure of trial data could trigger a short‑term price move and influence sector sentiment.
What to watch
Regulatory pathway (505(b)(2)) and compounded product status could limit commercial upside.
Background
Daré Bioscience is developing a topical sildenafil formulation for female sexual arousal disorder, a market with no approved treatments.
Ticker impact
Daré Bioscience disclosed Phase 1 clinical data for its Sildenafil Cream, the first public release of these results.
likely upward pressure as market prices in favorable safety and bioavailability profile
First-time disclosure of trial results, with clear safety signals, is material for a biotech and can move the stock.
Market effects
May lift sentiment for female sexual health therapeutics and related biotech peers.
Limited to US biotech sector; no broader regional effect.
Modest global relevance, primarily affecting investors tracking niche sexual health drugs.
Counterpoint
Data are early‑stage; investors may wait for Phase 2 results before committing.
Key entities
- companyDaré Bioscience, Inc.
NASDAQ‑listed biotech developing Sildenafil Cream.
- personAnnie Thurman
Medical Director presenting the data at SMSNA.
